fazamorexant   Click here for help

GtoPdb Ligand ID: 14135

Synonyms: compound of formula (II) [US20230149402] | YZJ 1139 | YZJ-1139 | YZJ1139
Approved drug
fazamorexant is an approved drug
Compound class: Synthetic organic
Comment: Fazamorexant (YZJ-1139) is a non-selective orexin receptor antagonist [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 66.62
Molecular weight 432.49
XLogP 1.78
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC(=C(C=C1)C2=NC=CC=N2)C(=O)N3[C@H]4CC[C@@H](COC5=CC=C(C=N5)F)[C@@H]3CC4
Isomeric SMILES CC1=CC(=C(C=C1)C2=NC=CC=N2)C(=O)N3[C@H]4CC[C@H]([C@@H]3CC4)COC5=NC=C(C=C5)F
InChI InChI=1S/C25H25FN4O2/c1-16-3-8-20(24-27-11-2-12-28-24)21(13-16)25(31)30-19-6-4-17(22(30)9-7-19)15-32-23-10-5-18(26)14-29-23/h2-3,5,8,10-14,17,19,22H,4,6-7,9,15H2,1H3/t17-,19-,22-/m0/s1
InChI Key PMJPLAGTPPVSRL-JLMWRMLUSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Fazamorexant (YZJ-1139) was progressd through clinical trials to evaluate safety and efficacy as a treatment for insomnia. First approval was granted by China's NMPA in May 2026 as an insomnia therapeutic.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05525637 Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder Phase 3 Interventional Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT06680505 Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder Phase 2 Interventional Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT06975514 Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder Phase 3 Interventional Shanghai Haiyan Pharmaceutical Technology Co., Ltd.